Jason McLellan, professor in the Department of Molecular Biosciences and Robert A. Welch Chair in Chemistry at UT, will be ...

McLellan, who will be inducted in Washington, D.C. on May 8, is among the youngest new inductees in hall of fame history.

Annemarie Hanekamp has overseen some of the most transformative changes in oncology over her years in Big Pharma. Now, she ...

COVID-19 vaccines were not associated with increased risk for thyroid diseases but were associated with increased risk for exacerbated hypothyroidism.

In a report released today, Asthika Goonewardene from Truist Financial assigned a Buy rating to BioNTech SE (BNTX – Research Report). The ...

Biopharma executives were busy Monday, striking high-value deals and providing updates on cancer, obesity and vaccine ...

Executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates as pan-tumor treatment approaches ...

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

BioNTech SE trades -13.2% away from its average analyst target price of $136.12 per share. The 20 analysts following the ...

Moderna now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of which will come in the second half of the year.

Shares of BioNTech fell 4% on Monday. Vaccine stocks are volatile after Moderna's updated revenue guidance for 2025, which ...

Truist Financial initiated coverage on shares of BioNTech (NASDAQ:BNTX – Free Report) in a research report released on Friday morning, Marketbeat.com reports. The firm issued a buy rating and a ...